Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

Lindsay Wilde, MD, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, John L. Wagner, MD, Onder Alpdogan, MD, Margaret Kasner, MDMSc, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Dolores Grosso, DNP, CRNP, Michael Millenson, Amy R. MacKenzie, MD, Allison Zibelli, MD, Neal Flomenberg, MD, Pierluigi Porcu, MD, Usama Gergis, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140719

Published: 2020

Journal Articles

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Zheng Zhou, Laurie H. Sehn, Alfred W. Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria A. Rodriguez, Auayporn Nademanee, Mark S. Kaminski, Myron S. Czuczman, Michael Millenson, Joyce Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg, Jane N. Winter

Blood (2014) 123 (6): 837–842.

https://doi.org/10.1182/blood-2013-09-524108

Published: 2014

Includes: Supplemental data

Journal Articles

Association Of Large Granular Lymphocytic Leukemia (LGL) With B-Cell Lymphoproliferative Disorders

Alan P. Z. Skarbnik, MD, Craig A. Portell, MD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Ramon V. Tiu, MD, Brad Pohlman, MD, Manuel G. Afable, II, Anjali S. Advani, MD, Robert M Dean, MD, Brian T. Hill, MD, PhD, Leonard J. Horwitz, MD, Deepa Jagadeesh, MD, MPH, Alan E. Lichtin, Christy Samaras, DO, Mikkael A. Sekeres, MD, MS, Michael Millenson, MD, Mitchell R Smith, MD, PhD

Blood (2013) 122 (21): 1387.

https://doi.org/10.1182/blood.V122.21.1387.1387

Published: 2013

Journal Articles

A Multicenter Phase II Study Of Bortezomib (VELCADE®) Combined With Rituximab For Untreated High Tumor Burden (HTB) Indolent Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up Of Outcomes and Examination Of Prognostic Factors

Andrew M Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Irene Helenowski, PhD, Michael Millenson, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD

Blood (2013) 122 (21): 1807.

https://doi.org/10.1182/blood.V122.21.1807.1807

Published: 2013

Journal Articles

SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study

Blood (2013) 122 (21): 86.

https://doi.org/10.1182/blood.V122.21.86.86

Published: 2013

Journal Articles

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

Alex F Herrera, MD, Allison Crosby-Thompson, Jonathan W. Friedberg, MD, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Joyce Niland, PhD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Ann S. LaCasce, MD

Blood (2012) 120 (21): 1610.

https://doi.org/10.1182/blood.V120.21.1610.1610

Published: 2012

Journal Articles

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Hossein Borghaei, DO, MS, Russell J. Schilder, MD, Samuel Litwin, PhD, Michael Millenson, MD, Adam D Cohen, MD, Linda Thibodeau, RN, Mitchell R Smith, MD, PhD

Blood (2012) 120 (21): 2753.

https://doi.org/10.1182/blood.V120.21.2753.2753

Published: 2012

Journal Articles

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Zheng Zhou, MD, PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Ann Vanderplas, MS, Allison Crosby-Thompson, Andrew D Zelenetz, MD, PhD, Gregory A. Abel, MD, MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark S. Kaminski, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Joyce Niland, PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2656.

https://doi.org/10.1182/blood.V120.21.2656.2656

Published: 2012

Journal Articles

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Makiko Ban-Hoefen, MD, Ann Vanderplas, MS, Jennifer L. Kelly, PhD, MPH, Allison Crosby-Thompson, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Joyce Niland, PhD, Ann LaCasce, MD, Jonathan W. Friedberg, MD

Blood (2012) 120 (21): 2669.

https://doi.org/10.1182/blood.V120.21.2669.2669

Published: 2012

Journal Articles

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database

Ann S. LaCasce, Jonathan L. Vandergrift, Maria A. Rodriguez, Gregory A. Abel, Allison L. Crosby, Myron S. Czuczman, Auayporn P. Nademanee, Douglas W. Blayney, Leo I. Gordon, Michael Millenson, Ann Vanderplas, Eva M. Lepisto, Andrew D. Zelenetz, Joyce Niland, Jonathan W. Friedberg

Blood (2012) 119 (9): 2093–2099.

https://doi.org/10.1182/blood-2011-07-369629

Published: 2012

Journal Articles

Results of Radiation Therapy for Primary Extranodal Lymphoma of the Head and Neck: A Report of Case Series

Aruna Turaka, MD, Li Tianyu, MS, Adam D Cohen, MD, Barbara Pro, MD, Michael Millenson, MD, Valentine Robu, MD, Tahseen I. Al-Saleem, MD, Mitchell R Smith, MD, PhD

Blood (2011) 118 (21): 4761.

https://doi.org/10.1182/blood.V118.21.4761.4761

Published: 2011

Journal Articles

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Andrew M. Evens, DO, MSc, Ann Vanderplas, M.S., Ann LaCasce, MD, MSc, Allison Crosby, MS, Auayporn Nademanee, M.D., Mark S. Kaminski, MD, Gregory A. Abel, MD, MPH, Michael Millenson, MD, Myron S. Czuczman, MD, Maria A. Rodriguez, MD, Joyce Niland, PhD, Andrew D Zelenetz, MD, PhD, Leo I. Gordon, MD, FACP, Jonathan Friedberg, MD

Blood (2011) 118 (21): 4112.

https://doi.org/10.1182/blood.V118.21.4112.4112

Published: 2011

Journal Articles

Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Karim E Abou-Nassar, MD, Ann Vanderplas, Jonathan W. Friedberg, MD, Gregory Abel, MD, MPH, Joyce Niland, PhD, Maria A. Rodriguez, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Allison Crosby, MS, Leo I Gordon, MD, FACP, Andrew D Zelenetz, MD, Ann LaCasce, MD, MSc

Blood (2010) 116 (21): 81.

https://doi.org/10.1182/blood.V116.21.81.81

Published: 2010

Journal Articles

Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Anita Kumar, MD, Ann Vanderplas, Ann S. LaCasce, MD, MSc, Maria A. Rodriguez, MD, Allison L. Crosby, MS, Eva Lepisto, MSc, MA, Myron S. Czuczman, MD, Auayporn Nademanee, M.D., Joyce Niland, PhD, Leo I. Gordon, MD, FACP, Michael Millenson, MD, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD, Gregory A. Abel, MD, MPH

Blood (2010) 116 (21): 1756.

https://doi.org/10.1182/blood.V116.21.1756.1756

Published: 2010

Journal Articles

R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project.

Ann LaCasce, MD, Jonathan L. Vandergrift, MS, Maria A. Rodriguez, MD, Allison L. Crosby, MS, Eva M. Lepisto, MSc, MA, Myron S. Czuczman, MD, Auayporn P. Nademanee, MD, Douglas W. Blayney, MD, Leo I. Gordon, MD, Michael Millenson, MD, Ann Vanderplas, Gregory A. Abel, MD, MPH, Andrew D. Zelenetz, MD, PhD, Jonathan W. Friedberg, MD

Blood (2009) 114 (22): 403.

https://doi.org/10.1182/blood.V114.22.403.403

Published: 2009

Journal Articles

Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.

Gregory A. Abel, MD, MPH, Ann Vanderplas, MS, Jonathan W. Friedberg, MD, Joyce Niland, PhD, Maria A. Rodriguez, MD, Myron S Czuczman, MD, Michael Millenson, MD, Allison L. Crosby, Leo I. Gordon, MD, Douglas W. Blayney, MD, Andrew D. Zelenetz, MD, PhD, Ann S. LaCasce, MD

Blood (2009) 114 (22): 1387.

https://doi.org/10.1182/blood.V114.22.1387.1387

Published: 2009

Journal Articles

CD4 Cell Count of More Than 250/Microl in the Peripheral Blood Is Associated with Improved Overall Survival in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Independent of the aaIPI

Hossein Borghaei, DO, MS, Mitchell Smith, MD, Ph.D., Michael Millenson, Tianyu Li, Danielle Shafer, DO, Tahseen I. Al-Saleem, MD

Blood (2008) 112 (11): 3775.

https://doi.org/10.1182/blood.V112.11.3775.3775

Published: 2008

Journal Articles

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan (Zevalin) and Gemicitabine in Patients with Non-Hodgkin’s Lymphoma.

Hossein Borghaei, DO, MS, Mitchell R. Smith, MD, Ph.D., Michael Millenson, MD, Linda Thibodeau, RN, Nicole Kamiensky, Russell J. Schilder, MD

Blood (2007) 110 (11): 4485.

https://doi.org/10.1182/blood.V110.11.4485.4485

Published: 2007

Journal Articles

Concordance with National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (CPGs): A Quality of Care Tool for Newly Diagnosed Patients (pts) with Mantle Cell Lymphoma (MCL).

Maria Alma Rodriguez, MD, Anna Ter Veer, MS, Auayporn Nademanee, M.D., Joyce Niland, Ph.D., Eva Lepisto, MS, Michelle Kho, MSc, Ann LaCasce, M.D., Jane Carrie Weeks, M.D., Myron Czuczman, M.D., Michael Millenson, M.D., Jonathan Friedberg, M.D., Andrew D. Zelenetz, M.D.

Blood (2006) 108 (11): 3328.

https://doi.org/10.1182/blood.V108.11.3328.3328

Published: 2006

Journal Articles

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma.

Hossein Borghaei, DO, MS, Mitchell Smith, MD, Ph.D., Michael Millenson, MD, Danielle Shafer, DO, Linda Thibodeau, RN, Russell Schilder, MD

Blood (2006) 108 (11): 4710.

https://doi.org/10.1182/blood.V108.11.4710.4710

Published: 2006

NARROW

COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Association Of Large Granular Lymphocytic Leukemia (LGL) With B-Cell Lymphoproliferative Disorders

A Multicenter Phase II Study Of Bortezomib (VELCADE®) Combined With Rituximab For Untreated High Tumor Burden (HTB) Indolent Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up Of Outcomes and Examination Of Prognostic Factors

SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database

Results of Radiation Therapy for Primary Extranodal Lymphoma of the Head and Neck: A Report of Case Series

Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project,

Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database

Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.

CD4 Cell Count of More Than 250/Microl in the Peripheral Blood Is Associated with Improved Overall Survival in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Independent of the aaIPI

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan (Zevalin) and Gemicitabine in Patients with Non-Hodgkin’s Lymphoma.

Concordance with National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (CPGs): A Quality of Care Tool for Newly Diagnosed Patients (pts) with Mantle Cell Lymphoma (MCL).

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only